Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK)

Radiation Research

Volumn 174, Issue 4, 2010, Pages 526-531

  Uckun, F M ^a,b   Dibirdik, I ^a,b   Qazi, S ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

^c GUSTAVUS ADOLPHUS COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS (9 O DIHYDROQUINIDINYL) PHTHALAZINE HYDROQUINIDINE 1,4 PHATHALAZINEDIYL DIETHER; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTILEUKEMIC AGENT; C 61; CLADRIBINE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GENISTEIN; METHOTREXATE; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; VINCRISTINE; 1,4-BIS(9-O DIHYDROQUINIDINYL)PHTHALAZINE HYDROQUINIDINE 1,4-PHATHALAZINEDIYL DIETHER; PHTHALAZINE; PHTHALAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CLONE; CHILD; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVE SITE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA RELAPSE; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOACTIVITY; RADIOSENSITIVITY; RADIOSENSITIZATION; SCHOOL CHILD; TREATMENT RESPONSE; WHOLE BODY RADIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; LEUKEMIA; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; TUMOR CELL LINE;

MURINAE;

ANIMALS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; MICE; OXIDATIVE STRESS; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RADIATION-SENSITIZING AGENTS; WHOLE-BODY IRRADIATION;

EID: 77956657968     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR2246.1     Document Type: Article

References (31)

1. M. E. Trigg, P. Gaynon and F. M. Uckun, in Cancer Medicine, 4th ed. (J. F. Holland, R. C. Bast, Jr., D. L. Morton, E. Fry, III, D. W. Kufe and R. L. Weichselbaum, Eds.), pp. 2945-2960. Williams & Wilkins, Baltimore, 1996.
2. P. S. Gaynon, R. E. Harris, A. J. Altman, B. C. Bostrom, J. C. Brenneman, R. Hawks, D. Steele, T. Zipf, D. O. Stram and M. E. Trigg, Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Childrens Oncology Group Study CCG-1941. J. Clin. Oncol. 24, 3150-3156 (2006). (Pubitemid 46638953)
3. L. C. Bailey, B. J. Lange, S. R. Rheinhold and N. J. Bunin, Bone marrow relapse in paediatric acute lymphoblastic leukemia. Lancet Oncol. 9, 873-883 (2008).
4. M. Eapen, E. Raetz, M. J. Zhang, C. Muehlenbein, M. Devidas, T. Abshire, A. Billett, A. Homans, B. Camitta and S. M. Davies, Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in second remission: a collaborative study of the Childrens Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 107, 4961-4967 (2006). (Pubitemid 43882651)
5. A. Roy, A. Cargill, S. Love, A. V. Moorman, S. Stoneham, A. Lim, P. J. Darbyshire, D. Lancaster, I. Hann and V. Saha, Outcome after first relapse in childhood acute lymphoblastic leukemia - lessons from the United Kingdom R2 trial. Br. J. Hematol. 130, 67-75 (2005). (Pubitemid 40979134)
6. F. M. Uckun, S. Morar and S. Qazi, Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukemias. Br. J. Haematol. 135, 500-508 (2006). (Pubitemid 44583414)
7. S. Malempati, P. S. Gaynon, H. Sather, M. K. La and L. C. Stork, Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Childrens Oncology Group study CCG-1952. J. Clin. Oncol. 25, 5800-5807 (2007).
8. F. M. Uckun, W. Jaszcz, M. Chandan-Langlie, K. G. Waddick, K. Gajl-Peczalska and C. W. Song, Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J. Clin. Invest. 91, 1044-1051 (1993). (Pubitemid 23095280)
9. F. M. Uckun and C. W. Song, Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood 81, 1323-1332 (1993). (Pubitemid 23067371)
10. F. M. Uckun, M. Chandan-Langlie, W. Jaszcz, V. Obuz, K. Waddick and C. W. Song, Radiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia. Cancer Res. 53, 1431-1436 (1993). (Pubitemid 23097128)
11. F. M. Uckun, S. Qazi, H. Ma, L. Tuel-Ahlgren and Z. Ozer, STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc. Natl. Acad. Sci. USA 107, 2902-2907 (2010).
12. F. M. Uckun, R. O. Ek, S. T. Jan, C. L. Chen and S. Qazi, Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukemia (ALL) Cells with a potent SYK inhibitory pentapeptide mimic. Br. J. Hematol. 149, 508-517 (2010).
13. F. M. Uckun, Z. Ozer, S. Qazi, L. Tuel-Ahlgren and C. Mao, Polo-like kinase 1 (PLK1) as a molecular target to overcome Sykmediated resistance of B-lineage acute lymphoblastic leukemia cells to oxidative stress. Br. J. Hematol. 148, 714-725 (2010).
14. F. M. Uckun, K. G. Waddick, S. Mahajan, X. Jun, M. Takata, J. Bolen and T. Kurosaki, BTK as a mediator of radiation-induced apoptosis in DT40 lymphoma B-cells. Science 273, 1096-1100 (1996). (Pubitemid 26278163)
15. F. M. Uckun, L. Tuel-Ahlgren, K. G. Waddick, X. Jun, J. Jin, D. E. Myers, R. B. Rowley, A. L. Burkhardt and J. B. Bolen, Physical and functional interactions between Lyn and p34cdc2 kinases in irradiated human B-cell precursors. J. Biol. Chem. 271, 6396-6397 (1996). (Pubitemid 26095449)
16. E. A. Sudbeck, X. Liu, R. K. Narla, S. Mahajan, S. Ghosh, C. Mao and F. M. Uckun, Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5, 1569-1582 (1999). (Pubitemid 29282966)
17. D. Zhu and F. M. Uckun, Calpain inhibitor II induces caspasedependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkins lymphoma cells as well as some solid tumor cells. Clin. Cancer Res. 6, 2456-2463 (2000). (Pubitemid 30399215)
18. F. M. Uckun, W. E. Evans, C. J. Forsyth, K. G. Waddick, L. T. Ahlgren, L. M. Chelstrom, A. Burkhardt, J. Bolen and D. E. Myers, Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267, 886-891 (1995).
19. S. Slavin and S. Stober, Spontaneous murine B cell leukemia. Nature 272, 624-626 (1977).
20. R. J. Fulton, J. W. Uhr and E. S. Vitetta, In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res. 48, 2626-2631 (1988).
21. F. M. Uckun, L. M. Chelstrom, J. D. Irvin, D. Finnegan, R. Gunther, J. Young, V. Kuebelbeck, D. E. Myers and L. L. Houston, In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia. Blood 79, 2649-2661 (1992).
22. K. G. Waddick, D. M. Finnegan, L. M. Chelstrom and F. M. Uckun, In vivo radiosensitizing effects of recombinant interleukin 6 on radiation resistant BCL-1 B-lineage leukemia cells in a murine syngeneic bone marrow transplant model system. Leuk. Lymphoma 19, 121-128 (1995).
23. L. N. Johnson, Protein tyrosine kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys. 42, 1-40 (2009).
24. T. H. Marsilje, K. L. Milkiewicz and D. G. Hangauer, The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives. Bioorg. Med. Chem. Lett. 10, 477-481 (2000). (Pubitemid 30153617)
25. G. Ye, R. Tiwari and K. Parang, Development of Src tyrosine kinase substrate binding site inhibitors. Curr. Opin. Investig. Drugs 9, 605-613 (2008). (Pubitemid 351777164)
26. R. M. Young, I. R. Hardy, R. L. Clarke, N. Lundy, P. Pine, B. C. Turner, T. A. Potter and Y. Refaeli, Mouse models of non- Hodgkins lymphoma reveal Syk as an important therapeutic target. Blood 113, 2508-2516 (2009).
27. A. Rinaldi, I. Kwee, M. Taborelli, C. Largo, S. Uccella, V. Martin, G. Poretti, G. Gaidano, G. Calabrese and F. Bertoni, Genomic and expression profiling identifies the B cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Hematol. 132, 303-316 (2006). (Pubitemid 43381537)
28. L. Leseux, S. M. Hamdi, T. Al Saati, F. Capilla, C. Recher, G. Laurent and C. Bezombes, Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108, 4156-4162 (2006). (Pubitemid 44913287)
29. M. P. Quiroga, K. Balahrishna, A. V. Krutova, M. Sivina, M. J. Keating, W. G. Wierda, V. Ghandi and J. A. Burger, B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114, 1029-1037 (2009).
30. S. Gobessi, L. Laurenti, P. G. Longo, L. Carsetti, V. Berno, S. Sica, G. Leone and D. G. Efremov, Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B-cells. Leukemia 23, 686-697 (2009).
31. C. K. Hahn, J. E. Berchuk, K. N. Ross, R. M. Kakoza and K. Clauser, Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16, 281-294 (2009).